Nurix Therapeutics Inc (NRIX)

$NRIX Healthcare technology. Testing key support. Volume pattern shows distribution. Growth concerns persisting.

$NRIX I added another few thousand shares and will keep doing so each week as long as it's $<10. Just bexo is worth the $685M cap in my opinion. If anything else works out it will be icing on the cake.

$NRIX "Heads up alert! Upcoming earnings on Thursday, 10/9/2025 for $NRIX Neutral (5.2) Financial Analysis: Nurix Therapeutics (NRIX) has been a notable mover in recent trading sessions, reflecting increased investor interest amidst higher-than-average trading volumes. However, the latest trends in earnings estimate revisions suggest potential headwinds that may impede sustained upward momentum in the near term. From a financial performance perspective, Nurix is currently positioned as a clinical-stage biopharmaceutical company, and thus, traditional metrics like the P/E ratio are not applicable due to its ongoing investment in research and development without a consistent revenue stream. The company's focus on pioneering novel protein degradation therapies places it at a strategic advantage in the biotech sector, especially with promising preclinical data from its IRAK4 degrader, GS-6791, which is advancing into clinical trials. Comparative analysis with industry peers indicates that while Nurix is in the early stages of its product lifecycle, its innovative pipeline and strategic partnerships could offer significant long-term upside. Upcoming Earnings Reports: Regarding upcoming earnings, Nurix Therapeutics is expected to report results that reflect its continued investment in R&D, aligning with its strategic focus on advancing its clinical pipeline. Historically, the company has demonstrated a commitment to expanding its scientific capabilities, although this has often resulted in earnings that fall short of market expectations due to high operational costs associated with drug development. Analyst consensus suggests that while near-term earnings may still be under pressure, positive developments in clinical trials could enhance investor sentiment and provide support for the stock. Investors will be closely watching management's guidance on trial progress and any updates on partnerships or collaborations that could impact future revenue streams. Sector Performance: The biotechnology sector, to which Nurix belongs, has experienced a mixed performance recently. While innovation and advancements in therapeutic areas continue to drive interest, the sector faces challenges such as regulatory scrutiny and volatility due to the speculative nature of early-stage biopharma companies. Despite these challenges, the sector remains a focal point for long-term investors seeking exposure to groundbreaking advancements in medicine. Nurix's focus on protein degradation, a cutting-edge therapeutic approach, aligns well with the sector's broader innovation trends, positioning it as a potential beneficiary of renewed investor interest in biotech innovations. - Funds were net sellers of $NRIX during the previous reporting quarter. - Funds with large holdings in $NRIX include: - Baker Brothers Advisors LP, MV: $44MM. Fund Rank: 71% - ARK Investment Management LLC, MV: $18MM. Fund Rank: 70% www.ark-invest.com - Ensign Peak Advisors, MV: $3MM. Fund Rank: 59% - Jasper Ridge Partners, MV: $1MM. Fund Rank: 65% - Last 10 days performance: 9% - Last 30 days performance: -1% - Last 90 days performance: -27% Some of the latest news articles: - Title: Nurix Therapeutics (NRIX) Soars 5.6%: Is Further Upside Left in the Stock? Publication Date: 9/25/2025 1:29:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/nurix-therapeutics-nrix-soars-5-132900489.html?.tsrc=rss - Title: Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis Publication Date: 9/17/2025 11:00:00 AM, Source: yahoo URL: https://finance.yahoo.com/news/nurix-therapeutics-presents-preclinical-data-110000675.html?.tsrc=rss - Title: KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates Publication Date: 9/11/2025 12:05:01 PM, Source: yahoo URL: https://finance.yahoo.com/news/kalvista-pharmaceuticals-inc-kalv-reports-120501852.html?.tsrc=rss - Title: Nurix Therapeutics to Participate in Upcoming Investor Conferences Publication Date: 8/28/2025 8:01:00 PM, Source: yahoo URL: https://finance.yahoo.com/news/nurix-therapeutics-participate-upcoming-investor-200100103.html?.tsrc=rss Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."

$NRIX I have been gradually adding to my position here in the $8's and $9's. Degraders are going to be a very significant class of drugs in the not so distant future, and IMO Nurix is the best company in the space. Don't quite understand the price action - last year it was $25. Now, they are further along in clinical development (all the news has been good), the biotech environment overall is in much better shape, and it's $9.40?

$NRIX million shares traded in the final hour today. Price popped 5% during the same period. I wonder what someone saw that enticed them to buy a million shares before close. 🤔

$NRIX started a position.

$NRIX something similar to "Sanofi licensing deal boosts Nurix shares" will occur soon. hold on tight. $TSLA $NVDA $AMD $JNJ

$NRIX Nurix Therapeutics, Inc. (NRIX) Stock Analysis: A Biotech Gem with 232% Potential Upside https://www.directorstalkinterviews.com/nurix-therapeutics-inc-nrix-stock-analysis-a-biotech-gem-with-232-potential-upside/4121216884 $NVDA $MSFT $NIO $BNTX

$NRIX is a promising biostock. $QBTS $BTC.X $AMZN $INTC

$NRIX is expected to skyrocket... hold your horses. $TSLA $AAPL $NVDA $QBTS